Clinical trials: Grade IV Malignant Glioma
WHO Grade 3 Glioma, WHO Grade 4 Glioma
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma
This clinical trial evaluates whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging is useful in differentiating between disease that has come…
- Trial name
- NCT06444412
- Testing
- Computed Tomography, Electronic Health Record Review, Ga 68 PSMA-11
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Glioblastoma, Malignant Glioma
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
The purpose of this study is to determine the feasibility and safety of administering CMV RNA-pulsed dendritic cells (DCs), also known as CMV-DCs, to children and young adults up to 35 years old with nWHO Grade IV glioma…
- Conditions
- Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme
- Trial name
- ATTAC-P (NCT03615404)
- Testing
- CMV-DCs with GM-CSF, Td (tetanus toxoid)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Gary Archer Ph.D.
Glioblastoma (GBM), Diffuse Midline Glioma (DMG)
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
This is a single-arm open-label phase 1 dose escalation/expansion trial assessing the safety and efficacy of concurrent intrathecal azacitidine and intrathecal nivolumab in recurrent high-grade glioma.
- Conditions
- Glioblastoma (GBM), Diffuse Midline Glioma (DMG), Astrocytoma, IDH-Mutant, Grade 4, Diffuse Hemispheric Glioma, H3 G34-Mutant
- Trial name
- NCT06896110
- Testing
- Nivolumab, Azacitidine (AZA), lumbar puncture
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Andrew P. Groves
High Grade Glioma
Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas
The primary goal of this study is evaluate T cell immune status and immune reconstitution and the association with specific cytokines in patients with newly diagnosed HGGs undergoing the standard RT/TMZ and adjuvant TMZ.
- Trial name
- NCT02041611
- Testing
- Blood collections
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
This phase I/II trial tests the safety, side effects best dose and effect of retifanlimab with or without difluoromethylornithine (DFMO) for the treatment of high grade gliomas that are growing, spreading, or getting worse…
- Conditions
- Anaplastic Oligodendroglioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Diffuse Astrocytoma
- Trial name
- NCT07468136
- Testing
- Biospecimen Collection, Eflornithine, Lumbar Puncture
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mayo Clinic
Glioma Glioblastoma Multiforme, High Grade Glioma (III or IV)
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Gliomas are the most common malignant brain tumors, which are often associated with high-grade tumors characterized by an inferior prognosis and low patient survival rates in both children and adults.
- Trial name
- NCT06687681
- Testing
- NK cell therapy
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Marzieh Ebrahimi
Brain and Central Nervous System Tumors, Lymphoma
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of DX-8951f in treating children who have advanced solid…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00004212
- Testing
- filgrastim, exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
WHO Grade III Gliomas, WHO Grade IV Gliomas
Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas
This is a single-center, open-label, multi-dose phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of ZSNeo-DC1.1, a personalized dendritic cell injection, in subjects with recurrent or…
- Trial name
- NCT06253234
- Testing
- personalized dendritic cell injection ZSNeo-DC1.1
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tiantan Hospital
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Low Grade Glioma
- Trial name
- NCT03233204
- Testing
- Olaparib
- Where
- 113 sites in United States, Puerto Rico
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Glioma, Glioblastoma Multiforme
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety of ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health Organization (WHO) grade III or IV malignant glioma.
- Trial name
- NCT02590263
- Testing
- Whole Brain Radiation, Temozolomide, ABT-414
- Where
- 22 sites in Japan
- Volunteers
- 53 people
- Sponsor
- AbbVie
Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
This phase I trial studies the side effects and best dose of EGFR/IL13Rα2 pool-chimeric antigen receptor (CAR) T cells when given through a thin, flexible tube into the brain (locoregional administration) in treating patients…
- Trial name
- NCT07544992
- Testing
- Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- City of Hope Medical Center
Malignant Glioma (WHO Grade III or IV)
Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
The primary objectives of the study are to determine the maximum tolerated dose (MTD) of Carboxyamidotriazole Orotate (CTO) when combined with standard dosing of bevacizumab among patients with recurrent malignant glioma (WHO…
- Trial name
- NCT01954030
- Testing
- CTO and Bevacizumab, CTO alone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Annick Desjardins
High Grade Glioma (III or IV)
Terameprocol in Treating Patients With Recurrent High Grade Glioma
This phase I trial studies the side effects and best dose of terameprocol in treating patients with high-grade glioma that has come back.
- Trial name
- NCT02575794
- Testing
- Terameprocol, Pharmacological Study
- Where
- 9 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma, Malignant Glioma
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
This study is for newly diagnosed WHO Grade IV malignant glioma patients to determine whether an investigational drug known as marizomib (MRZ) will improve the treatment of newly diagnosed glioblastoma patients by delaying the…
- Trial name
- NCT02903069
- Testing
- MRZ, TMZ, RT
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 66 people
- Sponsor
- Celgene
Glioblastoma Multiforme, Glioblastoma
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV
- Trial name
- ATTAC-II (NCT02465268)
- Testing
- pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of Florida
Malignant Glioma, WHO Grade III or IV Recurrent Glioma
Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma
Topotecan is a FDA-approved drug when given by intravenous injection, but it is not effective against brain tumors when given intravenously.
- Trial name
- NCT02278510
- Testing
- Topotecan, Gadolinium DTPA, Cleveland Multiport Catheter
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Michael Vogelbaum, MD, PhD
Brain Tumor, Recurrent, Malignant Glioma (WHO Grade III or IV)
Chronic CED of TPT for Recurrent Malignant Glioma
The primary goal of this study is to establish the safety of chronic Convection Enhanced Delivery (CED) of the chemotherapeutic drug Topotecan for patients with recurrent malignant glioma that harbors the Isocitrate Dehydrogenase…
- Conditions
- Brain Tumor, Recurrent, Malignant Glioma (WHO Grade III or IV), IDH1/IDH2 Mutation
- Trial name
- TPT CED rHGG (NCT06666712)
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Jeffrey N. Bruce
Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a…
- Conditions
- Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma
- Trial name
- NCT07301268
- Testing
- Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in…
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
- Trial name
- NCT05843253
- Testing
- Ribociclib, Everolimus, Temozolomide (TMZ)
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Nationwide Children's Hospital
Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
This pilot clinical trial compares gadobutrol with standard of care contrast agents, gadopentetate dimeglumine or gadobenate dimeglumine, before dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in diagnosing…
- Conditions
- Adult Anaplastic (Malignant) Meningioma, Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma
- Trial name
- NCT02967380
- Testing
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Gadobenate Dimeglumine, Gadobutrol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Southern California